Scripps Structural Heart Intervention and Imaging 2026

Videos Only no PDFs

The Scripps Structural Heart Intervention and Imaging course delivers a practical, state-of-the-art, live case-based review of structural heart disease interventions and cardiovascular imaging. Emphasizing multidisciplinary collaboration, the program features expert faculty, including interventional cardiologists, echocardiologists, electrophysiologists, cardiothoracic surgeons, anesthesiologists, and sonographers. The course will cover clinical guidelines on patient selection, pre-procedural evaluation, procedural techniques, imaging integration, and challenges, concluding with outcome assessments and future innovations in the field.

1. Build and optimize a multidisciplinary team of health care professionals to ensure appropriate management of patients with structural heart disease.
2. Identify the equipment and imaging technologies necessary to perform structural heart disease interventions.
3. Apply a comprehensive approach to the assessment of the aortic, mitral, and tricuspid valves, the interatrial septum, and the left and right ventricles, using echocardiography (TTE, TEE, and ICE), CT, and MRI for the purpose of the interventional treatment of these cardiac structures.
4. Outline the current indications for LAA closure, PFO closure, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), and mitral transcatheter edge to edge repair (TEER).
5. Evaluate echocardiographic and CT imaging before and after LAA closure, and identify and measure peri-device leaks, device-related thrombus, and other potential complications.
6. Identify appropriate treatment strategies for patients with mitral valve disease (i.e., TEER or TMVR) or tricuspid valve disease (i.e., TEER or TTVR) based upon imaging findings.
7. Incorporate live TEE multiplanar imaging to optimize transcatheter mitral and tricuspid valve intervention.
8. Apply 2D and 4D ICE during structural heart intervention.
9. Recognize the risk of left ventricular outflow tract obstruction after TMVR and coronary occlusion after TAVR and apply specific interventional strategies to prevent them (e.g., LAMPOON and BASILICA).
10. Integrate emerging data regarding surgical risk, including low and intermediate-risk patients into TAVR decision-making.
11. Recognize heart failure patients who might benefit from novel interventional strategies, such as interatrial shunt devices, to improve symptoms.
12. Optimize the anesthetic management of patients with reduced ejection fraction undergoing TEER or TMVR.
13. Employ best practices to safely manage potential complications of catheter-based therapies for structural heart disease.